S-LAM
Epidemiological factors of the Net survival of Acute Myeloid Leukemia
The major aim of this project is to estimate the net survival at 1, 3 and 5 years after a diagnosis of AML in an international level to identify any geographical distribution of survival.
The second objective is to evaluate the impact of various characteristics on survival or on excess mortality by geographical areas: i) the comorbidity at diagnosis using the Charlson Index, ii) the socio-economic level based on the European Deprivation Index and iii) the therapeutic management of AML.
Période du projet :
-
Membre(s) SESSTIM du projet :
Membre(s) hors SESSTIM du projet :
Morgane MOUNIER (Project coordinator)
Commanditaires :
INCa SHS-E-SP 2018 (SHSESP18-094)
Partenaires :
Registre des hémopathies malignes de Côte d’Or (Equipe du coordinateur).
SESSTIM, UMR 1252 Inserm/IRD/Aix-Marseille Université.
London School of Hygiene and Tropical Medicine (LSHTM).
Registre régional des Hémopathies Malignes de Basse Normandie.
Registre des Hémopathies Malignes de Gironde.
National Institute of Health Carlos III (“Miguel Servet” Program) & Spanish Ministry of Science and Innovation.
LBBE: Equipe Biostatistiques-Santé, Service de biostatistique – Centre Hospitalier Lyon sud.
Thèmes :
Problématique:
Acute myeloid leukemia (AML) is a rare disease with poorer prognosis. In France, except for promyelocytic forms, the 5-year net survival probability for the AML is stable and around 20% since more than 20 years except for youngster whom survival improved. This unfavorable prognosis is particularly marked in patients older than 65 years old at diagnosis, with a 5-year survival rate up to 5%. These results are comparable in all European countries. Nevertheless, there is no data available on AML survival by subtype although it has been shown from clinical trials data that AML represents a heterogeneous group with different prognosis by subtype.
Méthode :
For this purpose, we will use the worldwide population-based database collected in the CONCORD-2 project from 2000 to 2009. For age-categories, sex and period of diagnosis, the probability of net survival and the dynamic of the excess mortality rate over the time since diagnosis will be estimated: i) for the overall AML group and ii) specifically by AML subtype classified according to the ICD-O-3 and to the grouping proposed by the HAEMACARE consortium.
The second part of this work will be based on the database on 3 French cancer registry specialized in hematological malignancies (REPIH network), on national database in England and on different cancer registries in Spain.
